CN116898941A - Traditional Chinese medicine composition and application thereof, traditional Chinese medicine preparation and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition and application thereof, traditional Chinese medicine preparation and preparation method and application thereof Download PDFInfo
- Publication number
- CN116898941A CN116898941A CN202310905407.8A CN202310905407A CN116898941A CN 116898941 A CN116898941 A CN 116898941A CN 202310905407 A CN202310905407 A CN 202310905407A CN 116898941 A CN116898941 A CN 116898941A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- preparation
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 142
- 238000002360 preparation method Methods 0.000 title claims abstract description 74
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 239000002994 raw material Substances 0.000 claims abstract description 24
- 241000545744 Hirudinea Species 0.000 claims abstract description 20
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 19
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 18
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 18
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 18
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 8
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 8
- 244000061520 Angelica archangelica Species 0.000 claims abstract 3
- 206010029240 Neuritis Diseases 0.000 claims description 30
- 201000001119 neuropathy Diseases 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 19
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 239000003472 antidiabetic agent Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 3
- 229940126904 hypoglycaemic agent Drugs 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 38
- 239000008280 blood Substances 0.000 abstract description 38
- 230000000694 effects Effects 0.000 abstract description 25
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract description 13
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241000252212 Danio rerio Species 0.000 description 31
- 230000000052 comparative effect Effects 0.000 description 20
- 241000125175 Angelica Species 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 15
- 230000001603 reducing effect Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- 241000112528 Ligusticum striatum Species 0.000 description 11
- 229960004115 sitagliptin phosphate Drugs 0.000 description 11
- RTZRUVMEWWPNRR-UHFFFAOYSA-N tert-butyl n-(3-iodo-1h-pyrrolo[2,3-b]pyridin-5-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CN=C2NC=C(I)C2=C1 RTZRUVMEWWPNRR-UHFFFAOYSA-N 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 210000005036 nerve Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 210000000578 peripheral nerve Anatomy 0.000 description 7
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 4
- 108010000912 Egg Proteins Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 235000013345 egg yolk Nutrition 0.000 description 4
- 210000002969 egg yolk Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 230000008736 traumatic injury Effects 0.000 description 4
- 241000382455 Angelica sinensis Species 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010034568 Peripheral coldness Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000013011 mating Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- WTQYWNWRJNXDEG-UHFFFAOYSA-N 6-Hydroxy-hyoscyamin Natural products CN1C(C2)CC(O)C1CC2OC(=O)C(CO)C1=CC=CC=C1 WTQYWNWRJNXDEG-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 241000208173 Apiaceae Species 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000407170 Curcuma Species 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 241000963390 Curcuma wenyujin Species 0.000 description 1
- 235000003394 Curcuma wenyujin Nutrition 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 240000002373 Ficus pumila Species 0.000 description 1
- 235000006718 Ficus pumila Nutrition 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- WTQYWNWRJNXDEG-LEOABGAYSA-N anisodamine Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@H]3[C@@H](O)C[C@@H](C2)N3C)=CC=CC=C1 WTQYWNWRJNXDEG-LEOABGAYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- -1 decoction Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 208000010515 dystocia Diseases 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000011802 pulverized particle Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000004506 ultrasonic cleaning Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The application relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition and application thereof, a traditional Chinese medicine preparation and a preparation method and application thereof. The traditional Chinese medicine composition comprises the following raw materials in parts by weight: 10-50 parts of wine angelica, 10-50 parts of szechuan lovage rhizome, 10-50 parts of honeysuckle stem, 5-15 parts of curcuma longa and 1-5 parts of leech. The Chinese medicinal composition can be used for treating diabetic peripheral neuropathy, and has blood sugar lowering effect.
Description
Technical Field
The application relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition and application thereof, a traditional Chinese medicine preparation and a preparation method and application thereof.
Background
Diabetes is a metabolic disease characterized by hyperglycemia. Diabetic peripheral neuritis is the most important chronic complication of diabetes mellitus, and is also known as diabetic peripheral neuropathy in medicine, which is most frequently seen in peripheral symmetrical sensory and motor neuropathy and autonomic neuropathy. Patients with diabetic peripheral neuritis feel more symmetrical limb numbness, pain, burning sensation, hypoesthesia, epigastric distention, constipation, palpitation, localized hyperhidrosis, little sweat, cold hands and feet, etc.
Through better blood sugar control, the metabolic abnormality and even pathological change of nerves can be prevented and reversed, the symptoms can be lightened, and the progress of diabetic neuropathy can be delayed.
Comprehensive treatment of peripheral neuropathy of diabetes by Chinese and Western medicine finds: the western medicine mainly improves nerve microcirculation, antagonizes oxidative stress and neurotrophic treatment, however, clinical adverse reactions are larger, such as anisodamine can only generate medicine effect by using larger dosage, but partial patients can have adverse reactions such as dry mouth, flushed complexion, blurred vision, increased heart rate, difficult urination and the like.
Therefore, the traditional Chinese medicine composition for treating diabetic peripheral neuropathy and assisting in reducing blood sugar has important significance.
In view of this, the present application has been made.
Disclosure of Invention
The first aim of the application is to provide a traditional Chinese medicine composition which can treat diabetic peripheral neuropathy and has the function of reducing blood sugar.
The second aim of the application is to provide an application of a traditional Chinese medicine composition in preparing a medicine for treating peripheral neuritis.
The third aim of the application is to provide an application of a traditional Chinese medicine composition in preparing a hypoglycemic drug.
The fourth object of the application is to provide a traditional Chinese medicine preparation.
The fifth aim of the application is to provide a preparation method of the traditional Chinese medicine preparation, which has the advantages of simple and feasible operation, short process flow, high extraction efficiency and the like.
The sixth aim of the application is to provide an application of a traditional Chinese medicine preparation in preparing a medicine for treating peripheral neuritis.
The seventh aim of the application is to provide an application of a traditional Chinese medicine preparation in preparation of hypoglycemic drugs.
In order to achieve the above object of the present application, the following technical solutions are specifically adopted:
the application provides a traditional Chinese medicine composition, which comprises the following raw materials in parts by weight: 10-50 parts of wine angelica, 10-50 parts of szechuan lovage rhizome, 10-50 parts of honeysuckle stem, 5-15 parts of curcuma longa and 1-5 parts of leech.
The application also provides application of the traditional Chinese medicine composition in preparing medicines for treating peripheral neuritis.
Preferably, the peripheral neuritis comprises diabetic peripheral neuritis.
The application also provides application of the traditional Chinese medicine composition in preparation of hypoglycemic drugs.
The application provides a traditional Chinese medicine preparation, which comprises the traditional Chinese medicine composition.
The preparation method of the traditional Chinese medicine preparation provided by the application comprises the following steps: mixing the above materials, and decocting.
The application also provides application of the traditional Chinese medicine preparation in preparing a medicament for treating peripheral neuritis.
The application also provides application of the traditional Chinese medicine preparation in preparation of hypoglycemic drugs.
Compared with the prior art, the application has the beneficial effects that:
(1) The traditional Chinese medicine composition provided by the application not only has a good treatment effect on diabetic peripheral neuropathy, but also has the effect of reducing blood sugar.
(2) The traditional Chinese medicine composition provided by the application has small toxic and side effects and easily available raw materials.
Drawings
In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings that are needed in the description of the embodiments or the prior art will be briefly described, and it is obvious that the drawings in the description below are some embodiments of the present application, and other drawings can be obtained according to the drawings without inventive effort for a person skilled in the art.
FIG. 1 is a comparative bar graph of the glucose levels of zebra fish after treatment with the present application provided normal control, model control, sitagliptin phosphate and the traditional Chinese medicine decoction of example 1;
FIG. 2 is a typical diagram of neutrophils around zebra fish nerves after treatment with the present application provided with a normal control group, a model control group, sitagliptin phosphate and the traditional Chinese medicine decoction of example 1;
fig. 3 is a comparative bar graph of the numbers of neutrophils around zebra fish nerves after treatment with the present application, normal control, model control, sitagliptin phosphate and the traditional Chinese medicine decoction of example 1.
Detailed Description
The technical solution of the present application will be clearly and completely described below with reference to the accompanying drawings and detailed description, but it will be understood by those skilled in the art that the examples described below are some, but not all, examples of the present application, and are intended to be illustrative of the present application only and should not be construed as limiting the scope of the present application. All other embodiments, which can be made by those skilled in the art based on the embodiments of the application without making any inventive effort, are intended to be within the scope of the application. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
In a first aspect, the application provides a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for treating diabetic peripheral neuropathy and assisting in reducing blood sugar, which comprises the following raw materials in parts by weight: 10-50 parts of angelica sinensis, including, for example, but not limited to, any one of 15 parts, 20 parts, 25 parts, 30 parts, 35 parts, 40 parts, 45 parts of spot values or range values between any two; 10-50 parts of ligusticum wallichii, for example, including but not limited to 15 parts, 20 parts, 25 parts, 30 parts, 35 parts, 40 parts, 45 parts of any one point value or any range value between the two; 10-50 parts of honeysuckle stem, for example, including but not limited to any one of 15 parts, 20 parts, 25 parts, 30 parts, 35 parts, 40 parts, 45 parts of spot value or range value between any two; 5-15 parts of curcuma longa, for example, including but not limited to any one of 7 parts, 9 parts, 10 parts, 12 parts, 14 parts or a range value between any two, and 1-5 parts of leech, for example, including but not limited to any one of 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts or a range value between any two.
The wine radix Angelicae sinensis is processed product of dried root of Angelica sinensis Diels of Umbelliferae. The wine Chinese angelica is mainly used for enriching and activating blood, regulating menstruation and relieving pain, and relaxing bowel, and is used for treating blood deficiency and sallow complexion, dizziness and palpitation, irregular menstruation, amenorrhea and dysmenorrhea, deficiency-cold abdominal pain, constipation due to intestinal dryness, rheumatalgia, traumatic injury and carbuncle and ulcer.
Chuan Xiong is pungent and warm in nature. Is mainly used for activating blood circulation to dissipate blood stasis, dispelling wind and relieving pain. For headache, dizziness, hypochondriac pain, abdominal pain, cold arthralgia, spasm of tendons, amenorrhea, dystocia, puerperal stasis, block pain, carbuncle, cellulitis and pyocutaneous disease. Can be used for treating menoxenia, amenorrhea, dysmenorrhea, abdominal pain, chest and hypochondrium pain, traumatic injury, headache, and rheumatalgia.
Caulis Lonicerae is also known as Ficus pumila, caulis seu radix salicylate or caulis Stephaniae Japonicae. Has effects of clearing heat and detoxicating, dispelling pathogenic wind and dredging collaterals. Can be used for treating epidemic febrile disease, skin sore, carbuncle, toxic swelling, dysentery with blood, rheumatic arthralgia, and joint redness, swelling and pain.
The dried rhizome of Curcuma wenyujin Y.H.Chen et C.Ling of Curcuma of Zingiberaceae is mainly used for breaking blood, promoting qi circulation, dredging channels and relieving pain. Can be used for treating amenorrhea due to blood stagnation, abdominal pain during menstruation, thoracocentesis, rheumatalgia, shoulder and arm pain, and traumatic injury.
Leech is neutral in nature, salty and bitter in taste, and enters liver meridian. Has effects of removing blood stasis, dredging channels, and eliminating symptoms. Can be used for treating amenorrhea due to blood stasis, abdominal mass, traumatic injury, and pain in heart and abdomen.
Among the above prescriptions, wine angelica is sweet and warm in nature, has the effects of replenishing blood, regulating menstruation, activating blood and relieving pain, and is used for treating arthralgia syndrome due to blood deficiency and blood stasis; ligusticum wallichii has the effects of promoting blood circulation, activating qi-flowing, dispelling wind and relieving pain; the honeysuckle stem has the effects of clearing heat and detoxicating, and activating meridians to stop pain; the three medicines are reused as monarch medicines, and have the effects of nourishing blood, activating blood, detoxifying and relieving pain, thus embodying the large method of nourishing blood, activating blood and relieving pain.
Wenyujin is a theory of "the traditional Chinese medicine is used for promoting qi circulation and blood circulation", and is a ministerial drug in the recipe.
Leech has the effects of removing blood stasis and eliminating mass, and is slightly used as an adjuvant drug because of its strong blood-breaking power. The five herbs are divided into different types and are indispensable.
The traditional Chinese medicine considers that the diabetic peripheral neuropathy belongs to the category of arthralgia, and the root of the diabetic peripheral neuropathy is blood stasis and obstruction of collaterals. The traditional Chinese medicine composition provided by the application has a good treatment effect on diabetic peripheral neuropathy and can also assist in reducing blood sugar by scientifically proportioning the traditional Chinese medicine raw materials to enable the traditional Chinese medicine raw materials to be matched with each other.
In addition, the traditional Chinese medicine composition provided by the application has the advantages of small toxic and side effects, simple and easily available raw materials and the like.
In order to obtain the traditional Chinese medicine composition with better treatment effect, the dosage of each raw material is optimized, and specifically, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 20-40 parts of wine angelica, 20-40 parts of szechuan lovage rhizome, 20-40 parts of honeysuckle stem, 7-13 parts of curcuma longa and 2-4 parts of leech.
In a preferred embodiment, the traditional Chinese medicine composition comprises the following raw materials in parts by weight: 30 parts of wine angelica, 30 parts of ligusticum wallichii, 30 parts of honeysuckle stem, 9 parts of curcuma longa and 3 parts of leech.
In a second aspect, the application provides application of the traditional Chinese medicine composition in preparation of a medicine for treating peripheral neuritis.
In a preferred embodiment, the peripheral neuritis comprises diabetic peripheral neuritis, i.e. diabetic peripheral neuropathy.
In a third aspect, the application provides application of the traditional Chinese medicine composition in preparation of hypoglycemic drugs.
It is understood that the above-mentioned drugs for treating peripheral neuritis also have the effect of reducing blood sugar. And/or, the hypoglycemic agent also has the effect of treating peripheral neuritis.
In a specific embodiment, the traditional Chinese medicine composition is decocted to obtain a liquid medicine, and the liquid medicine is divided into 200 milliliters per bag, and the usage is 1 bag per time, 2 times per day and is orally taken.
In a fourth aspect, the application provides a traditional Chinese medicine preparation, which comprises the traditional Chinese medicine composition.
The traditional Chinese medicine preparation provided by the application has the function of reducing blood sugar while treating diabetic peripheral neuropathy, and can improve diabetes symptoms.
In a preferred embodiment, the Chinese medicinal preparation further comprises pharmaceutically acceptable auxiliary materials. Among them, the auxiliary materials include, for example, disintegrants, lubricants, binders, and the like, but are not limited thereto.
In a preferred embodiment, the dosage form of the Chinese medicinal preparation comprises a pharmaceutically acceptable dosage form, such as decoction, pill, lozenge, granule, powder, paste, capsule, etc., but is not limited thereto.
In a fifth aspect, the present application provides a preparation method of the above-mentioned Chinese medicinal preparation, in particular to a preparation method of decoction (i.e. decoction), which specifically comprises the following steps: mixing the above materials, and decocting.
The preparation method has the advantages of simple and easy operation, short process flow, high extraction efficiency and the like.
It will be appreciated that adjuvants, such as water, are also added during the decoction process.
The temperature and time of the decoction, the water adding amount and other parameters can be any and conventional parameters, and the application is not limited to the above.
In a preferred embodiment, the preparation method of the traditional Chinese medicine preparation of the decoction comprises the following steps: decocting the Chinese medicinal composition with water, concentrating, and filtering to obtain Chinese medicinal preparation. More preferably, the method further comprises the step of soaking the Chinese medicinal composition before the decoction. More preferably, when in decoction, the mass ratio of the traditional Chinese medicine composition to water is 1:6 to 9.
In a specific embodiment, the preparation method of the traditional Chinese medicine preparation of the decoction specifically comprises the following steps: weighing the traditional Chinese medicine composition according to the parts by weight, and soaking the traditional Chinese medicine composition in 1600ml of purified water for 0.5h; then decocting the Chinese medicinal composition with the soaking solution, boiling with strong fire, boiling with slow fire for 1h, and filtering with 100 mesh sieve to obtain about 400ml oral liquid.
It is understood that the preparation method of the traditional Chinese medicine preparation is not limited to the preparation method of the decoction, and any preparation method of other dosage forms such as powder, paste, pill, lozenge, granule and the like which are conventional in the prior art can be adopted.
In a preferred embodiment, the preparation method of the traditional Chinese medicine preparation of the powder comprises the following steps: drying and sterilizing the traditional Chinese medicine composition, crushing and sieving the traditional Chinese medicine composition with a 20-60-mesh sieve, extracting active ingredients in the obtained undersize product by a supercritical low-temperature extraction method, and drying the undersize product to obtain a powdery traditional Chinese medicine preparation. More preferably, the drying before pulverization and the drying after extraction of the active ingredient have a temperature of 50 ℃ or less. More preferably, the method further comprises the step of passing the obtained powdery drug through a 200-300 mesh sieve after extracting the active ingredient and drying.
In a specific embodiment, the preparation method of the traditional Chinese medicine preparation of the powder specifically comprises the following steps: drying the above Chinese medicinal composition at 30deg.C, sterilizing in a double leaf sterilizing cabinet, pulverizing into particles with 20 mesh sieve, extracting active ingredients of the pulverized particles by supercritical low temperature extraction method, drying at 40deg.C, pulverizing the dried medicinal materials, and sieving with 200 mesh sieve to obtain powdered Chinese medicinal preparation.
In a sixth aspect, the application provides an application of the traditional Chinese medicine preparation in preparing a medicine for treating peripheral neuritis.
In a preferred embodiment, the peripheral neuritis comprises diabetic peripheral neuritis.
In a seventh aspect, the application provides application of the traditional Chinese medicine preparation in preparation of hypoglycemic drugs.
In a preferred embodiment, in the above-mentioned Chinese medicinal preparation, the medicament for treating peripheral neuritis also has the effect of reducing blood sugar, and/or the medicament for reducing blood sugar also has the effect of treating peripheral neuritis.
Embodiments of the present application will be described in detail below with reference to examples, but it will be understood by those skilled in the art that the following examples are only for illustrating the present application and should not be construed as limiting the scope of the present application. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1
The traditional Chinese medicine composition provided by the embodiment comprises the following raw materials in parts by mass: 30 parts of wine angelica, 30 parts of ligusticum wallichii, 30 parts of honeysuckle stem, 9 parts of curcuma longa and 3 parts of leech.
The method for preparing the traditional Chinese medicine preparation by adopting the traditional Chinese medicine composition comprises the following steps: mixing the above materials, adding 7 times of water into the mixture, soaking for 0.5 hr, decocting, boiling with strong fire, decocting with slow fire for 1 hr, and filtering with 100 mesh sieve to obtain Chinese medicinal preparation (i.e. Chinese medicinal decoction).
Example 2
The traditional Chinese medicine composition provided by the embodiment comprises the following raw materials in parts by mass: 20 parts of wine angelica, 20 parts of ligusticum wallichii, 20 parts of honeysuckle stem, 7 parts of curcuma longa and 2 parts of leech.
The method for preparing the traditional Chinese medicine preparation by adopting the traditional Chinese medicine composition is the same as that of the embodiment 1.
Example 3
The traditional Chinese medicine composition provided by the embodiment comprises the following raw materials in parts by mass: 40 parts of wine angelica, 40 parts of szechuan lovage rhizome, 40 parts of honeysuckle stem, 13 parts of curcuma longa and 4 parts of leech.
The method for preparing the traditional Chinese medicine preparation by adopting the traditional Chinese medicine composition is the same as that of the embodiment 1.
Example 4
The traditional Chinese medicine composition provided by the embodiment comprises the following raw materials in parts by mass: 10 parts of wine angelica, 10 parts of ligusticum wallichii, 10 parts of honeysuckle stem, 5 parts of curcuma longa and 1 part of leech.
The method for preparing the traditional Chinese medicine preparation by adopting the traditional Chinese medicine composition is the same as that of the embodiment 1.
Example 5
The traditional Chinese medicine composition provided by the embodiment comprises the following raw materials in parts by mass: 50 parts of wine angelica, 50 parts of ligusticum wallichii, 50 parts of honeysuckle stem, 15 parts of curcuma longa and 5 parts of leech.
The method for preparing the traditional Chinese medicine preparation by adopting the traditional Chinese medicine composition is the same as that of the embodiment 1.
Example 6
The traditional Chinese medicine composition provided by the embodiment comprises the following raw materials in parts by mass: 35 parts of wine angelica, 30 parts of ligusticum wallichii, 25 parts of honeysuckle stem, 10 parts of curcuma longa and 4 parts of leech.
The method for preparing the traditional Chinese medicine preparation by adopting the traditional Chinese medicine composition is the same as that of the embodiment 1.
Comparative example 1
The traditional Chinese medicine composition provided by the comparative example comprises the following raw materials in parts by mass: 42.5 parts of ligusticum wallichii, 42.5 parts of honeysuckle stem, 12.8 parts of curcuma longa and 4.2 parts of leech.
The method for preparing the traditional Chinese medicine preparation by adopting the traditional Chinese medicine composition is the same as that of the embodiment 1.
Comparative example 2
The traditional Chinese medicine composition provided by the comparative example comprises the following raw materials in parts by mass: 42.5 parts of wine angelica, 42.5 parts of honeysuckle stem, 12.8 parts of curcuma longa and 4.2 parts of leech.
The method for preparing the traditional Chinese medicine preparation by adopting the traditional Chinese medicine composition is the same as that of the embodiment 1.
Comparative example 3
The traditional Chinese medicine composition provided by the comparative example comprises the following raw materials in parts by mass: 42.5 parts of wine angelica, 42.5 parts of ligusticum wallichii, 12.8 parts of curcuma longa and 4.2 parts of leech.
The method for preparing the traditional Chinese medicine preparation by adopting the traditional Chinese medicine composition is the same as that of the embodiment 1.
Comparative example 4
The traditional Chinese medicine composition provided by the comparative example comprises the following raw materials in parts by mass: 32.9 parts of wine angelica, 32.9 parts of szechuan lovage rhizome, 32.9 parts of honeysuckle stem and 3.3 parts of leech.
The method for preparing the traditional Chinese medicine preparation by adopting the traditional Chinese medicine composition is the same as that of the embodiment 1.
Comparative example 5
The traditional Chinese medicine composition provided by the comparative example comprises the following raw materials in parts by mass: 30.9 parts of wine angelica, 30.9 parts of szechuan lovage rhizome, 30.9 parts of honeysuckle stem and 9.3 parts of curcuma longa.
The method for preparing the traditional Chinese medicine preparation by adopting the traditional Chinese medicine composition is the same as that of the embodiment 1.
Comparative example 6
The traditional Chinese medicine composition provided by the comparative example comprises the following raw materials in parts by mass: 30 parts of wine angelica, 30 parts of ligusticum wallichii, 30 parts of honeysuckle stem, 20 parts of curcuma longa and 10 parts of leech.
The method for preparing the traditional Chinese medicine preparation by adopting the traditional Chinese medicine composition is the same as that of the embodiment 1.
Test examples
Pharmacodynamic experiments
1. Detection material
1.1. Sample formulation information
Traditional Chinese medicine decoction: the traditional Chinese medicine preparations prepared in the above examples and comparative examples are directly used as stock solutions.
Positive control: the sitagliptin phosphate tablet, abbreviated as sitagliptin phosphate, orange-yellow tablet, lot number T027963, merck Sharp & Dohme Italia SPA, was stored in the shade. 3.50mg/mL mother liquor was prepared with ultrapure water, sonicated and stored at 4 ℃.
1.2. Experimental animal
Zebra fish are all cultivated in water for fish cultivation at 28 deg.C (water quality: 200mg instant sea salt is added into 1L reverse osmosis water, conductivity is 450-550 mu S/cm, pH is 6.5-8.5, hardness is 50-100 mg/LCaCO) 3 ) By nourishingThe fish center breeds and provides that experimental animals use license number as follows: SYXK (Zhe) 2022-0004. The feeding management meets the requirements of international AAALAC authentication (authentication number: 001458).
Wild type AB strain zebra fish is bred in a natural pairing mating breeding mode. Zebra fish aged 5 days after fertilization (5 dpf) is used for auxiliary blood sugar reduction efficacy maximum detection concentration (MTC) of traditional Chinese medicine decoction and efficacy evaluation thereof.
The transgenic neutrophil fluorescent zebra fish Tg (mpx: EGFP) strain is hybridized with the peripheral motor nerve green fluorescent zebra fish Tg (NBT: MAPT-GFP) strain, and the natural pairing mating propagation mode is adopted. Zebra fish with the age of 5dpf is used for detecting the effect of eliminating peripheral nerve inflammation of the traditional Chinese medicine decoction.
1.3. Instrument, consumable and reagent
Dissecting microscope (SZX 7, OLYMPUS, japan); CCD camera (VertA 1, shanghai Tusen Vision technologies Co., ltd.); electrokinetically focused continuously variable magnification fluorescence microscope (AZ 100, nikon, japan); precision electronic balances (CP 214, OHAUS, USA); glucometer (ACCU-CHEK Performa, roche diagnostics (Shanghai), inc.; high-speed centrifuges (TG 16G, shanghai ihe biotechnology limited, china); ultrasonic cleaning machine (JP-010T, shenzhen clean Equipment Co., ltd., china); full-automatic sample rapid grinding apparatus (JXFSPRP-24L, shanghai Jijing laboratory equipment science and technology, china).
Pure egg yolk powder (lot 20200809, argin biotechnology, inc., china, zhejiang); glucose (lot number F2209126, china, gladine biochemical technologies inc.); absolute ethanol (lot 20210107, national pharmaceutical systems chemical company, china); blood glucose meter test paper (lot 478829, roche diagnostics products (Shanghai), china).
2. Detection method and detection result
Mtc assay
The 5dpf wild type AB strain zebra fish were randomly selected in beakers, and 30 zebra fish were treated per beaker (each experimental group). The Chinese medicinal decoction prepared in example 1 was diluted with water to a concentration of 6.25. Mu.L/mL, 12.5. Mu.L/mL, 25. Mu.L/mL, 50. Mu.L/mL and 100. Mu.L/mL, respectively, while setting a normal control group and a model control group, each beaker having a capacity of 25mL. Except for a normal control group, each experimental group Bai Tianshui was given a 0.15% egg yolk powder solution and a 3% glucose solution at night to establish a zebra fish hyperglycemia model. During sample treatment, the number of dead zebra fish per experimental group was counted daily and dead zebra fish were removed in time. After treatment at 28℃for 4 days, the MTC of the traditional Chinese medicine decoction to the model zebra fish was measured, and the results are shown in Table 1.
TABLE 1 MTC test results of traditional Chinese medicine decoction on model Zebra fish
As can be seen from Table 1, under the experimental conditions, the MTC of the traditional Chinese medicine decoction to the model zebra fish was 12.5 mu L/mL.
2.2. Auxiliary blood sugar reducing effect
The 5dpf wild type AB strain zebra fish were randomly selected in beakers, and 30 zebra fish were treated per beaker (experimental group). The Chinese medicinal decoction prepared in example 1 was diluted with water to a concentration of 3.125. Mu.L/mL, 6.25. Mu.L/mL and 12.5. Mu.L/mL, respectively, and examples 2-6 and comparative examples 2-6 were diluted with water to a concentration of 6.25. Mu.L/mL, respectively, and the positive control sitagliptin phosphate concentration was 350. Mu.g/mL, while setting the normal control group and the model control group, with a beaker capacity of 25mL. Except for a normal control group, each experimental group Bai Tianshui was given a 0.15% egg yolk powder solution and a 3% glucose solution at night to establish a zebra fish hyperglycemia model. After 2d treatment at 28 ℃, zebra fish is washed 3 times by water for fish culture, data are collected by a glucometer, the glucose level of the zebra fish is analyzed and counted, and the effect of the traditional Chinese medicine decoction for assisting in reducing blood sugar is evaluated according to the statistical analysis result of the index. Statistical treatment results are expressed in mean+ -SE. Statistical analysis was performed with SPSS26.0 software, p <0.05 indicated that the differences were statistically significant. The test results of the hypoglycemic test are shown in table 2.
TABLE 2 evaluation of hypoglycemic efficacy test results
P <0.05, p <0.01, p <0.001 compared to model control.
As shown in Table 2, the Chinese medicinal decoction prepared by the embodiments of the application has good blood sugar reducing effect. In each comparative example, the blood sugar lowering effect was reduced due to the lack of components or improper proportions.
In addition, a comparative bar graph of zebra fish glucose levels after treatment with the normal control, model control, sitagliptin phosphate and the traditional Chinese medicine decoction of example 1 (decoction at concentrations of 3.125. Mu.L/mL, 6.25. Mu.L/mL and 12.5. Mu.L/mL, respectively) is shown in FIG. 1.
2.3. Evaluation of peripheral nerve inflammation resolution efficacy
The 5dpf transgenic neutrophil fluorescence and peripheral motor nerve green fluorescence hybrid strain zebra fish is randomly selected in beakers, and 30 zebra fish are treated in each beaker (experimental group). The Chinese medicinal decoction prepared in example 1 was diluted with water to a concentration of 3.125. Mu.L/mL, 6.25. Mu.L/mL and 12.5. Mu.L/mL, respectively, and examples 2-6 and comparative examples 2-6 were diluted with water to a concentration of 6.25. Mu.L/mL, respectively, and the positive control sitagliptin phosphate concentration was 350. Mu.g/mL, while setting the normal control group and the model control group, with a beaker capacity of 25mL. Except for a normal control group, each experimental group Bai Tianshui was given a 0.15% egg yolk powder solution and a 3% glucose solution at night to establish a zebra fish hyperglycemia model. After treatment for 4D at 28 ℃, 10 zebra fish are randomly selected from each group, photographed under a fluorescence microscope, and the pictures are saved, analyzed and data are collected by NIS-Elements D3.20 advanced image processing software, the number of neutrophils around the zebra fish nerves is analyzed and counted, and the effect of eliminating the inflammation of the nerves around the traditional Chinese medicine decoction is evaluated according to the statistical analysis result of the index. Statistical treatment results are expressed in mean+ -SE. Statistical analysis was performed with SPSS26.0 software, p <0.05 indicated that the differences were statistically significant. The peripheral nerve inflammation regression test results are shown in table 3.
TABLE 3 evaluation of peripheral nerve inflammation resolution efficacy test results
P <0.01 and p <0.001 compared to model control.
As shown in Table 3, the Chinese medicinal decoction prepared by the embodiments of the application has good effect of eliminating peripheral nerve inflammation. In each comparative example, the decrease in the efficacy of the regression of peripheral nerve inflammation was caused by the lack of components or improper proportions.
Further, typical diagrams of the perinerve neutrophils of zebra fish after treatment of the normal control group, the model control group, the sitagliptin phosphate and the traditional Chinese medicine decoction of example 1 (decoction with the concentration of 3.125. Mu.L/mL, 6.25. Mu.L/mL and 12.5. Mu.L/mL after dilution) are shown in FIG. 2. Specifically, the dashed line box in fig. 2 is the zebra fish analysis site, fig. 2 (a) corresponds to the normal control group, fig. 2 (b) corresponds to the model control group, fig. 2 (c) corresponds to sitagliptin phosphate (concentration is 350 μg/mL), fig. 2 (d) corresponds to the traditional Chinese medicine decoction of example 1 diluted to a concentration of 3.125 μl/mL, fig. 2 (e) corresponds to the traditional Chinese medicine decoction of example 1 diluted to a concentration of 6.25 μl/mL, and fig. 2 (f) corresponds to the traditional Chinese medicine decoction of example 1 diluted to a concentration of 12.5 μl/mL.
In addition, a comparison bar graph of the numbers of neutrophils around zebra fish nerves after treatment of the normal control group, the model control group, sitagliptin phosphate and the traditional Chinese medicine decoction of example 1 (decoction with the concentration of 3.125. Mu.L/mL, 6.25. Mu.L/mL and 12.5. Mu.L/mL after dilution respectively) is shown in FIG. 3.
According to the test results of the blood sugar reducing effect and the peripheral nerve inflammation fading effect, the traditional Chinese medicine composition provided by the application not only can treat diabetic peripheral neuropathy, but also has the blood sugar reducing effect, and can be used for preparing medicines for treating peripheral neuritis and blood sugar reducing medicines.
While the application has been illustrated and described with reference to specific embodiments, it is to be understood that the above embodiments are merely illustrative of the technical aspects of the application and not restrictive thereof; those of ordinary skill in the art will appreciate that: modifications may be made to the technical solutions described in the foregoing embodiments, or equivalents may be substituted for some or all of the technical features thereof, without departing from the spirit and scope of the present application; such modifications and substitutions do not depart from the spirit of the corresponding technical solutions; it is therefore intended to cover in the appended claims all such alternatives and modifications as fall within the scope of the application.
Claims (10)
1. The traditional Chinese medicine composition is characterized by comprising the following raw materials in parts by weight: 10-50 parts of wine angelica, 10-50 parts of szechuan lovage rhizome, 10-50 parts of honeysuckle stem, 5-15 parts of curcuma longa and 1-5 parts of leech.
2. The traditional Chinese medicine composition according to claim 1, wherein the traditional Chinese medicine composition comprises the following raw materials in parts by mass: 20-40 parts of wine angelica, 20-40 parts of szechuan lovage rhizome, 20-40 parts of honeysuckle stem, 7-13 parts of curcuma longa and 2-4 parts of leech.
3. The use of a Chinese medicinal composition according to claim 1 or 2 in the preparation of a medicament for the treatment of peripheral neuritis;
preferably, the peripheral neuritis comprises diabetic peripheral neuritis.
4. Use of a Chinese medicinal composition according to claim 1 or 2 in the preparation of a hypoglycemic agent.
5. A Chinese medicinal preparation, comprising the Chinese medicinal composition according to claim 1 or 2.
6. The traditional Chinese medicine preparation according to claim 5, further comprising pharmaceutically acceptable auxiliary materials.
7. The traditional Chinese medicine preparation according to claim 5, wherein the dosage form of the traditional Chinese medicine preparation comprises at least one of decoction, pill, lozenge, granule, powder, ointment and capsule.
8. The method for preparing a Chinese medicinal preparation according to any one of claims 5 to 7, comprising the steps of: mixing the above materials, and decocting.
9. The use of a Chinese medicinal preparation according to any one of claims 5 to 7 in the manufacture of a medicament for the treatment of peripheral neuritis.
10. The use of a Chinese medicinal preparation according to any one of claims 5 to 7 in the preparation of a hypoglycemic agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310905407.8A CN116898941B (en) | 2023-07-21 | 2023-07-21 | Traditional Chinese medicine composition and application thereof, traditional Chinese medicine preparation and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310905407.8A CN116898941B (en) | 2023-07-21 | 2023-07-21 | Traditional Chinese medicine composition and application thereof, traditional Chinese medicine preparation and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116898941A true CN116898941A (en) | 2023-10-20 |
| CN116898941B CN116898941B (en) | 2024-04-30 |
Family
ID=88356305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310905407.8A Active CN116898941B (en) | 2023-07-21 | 2023-07-21 | Traditional Chinese medicine composition and application thereof, traditional Chinese medicine preparation and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116898941B (en) |
Citations (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1075880A (en) * | 1992-10-10 | 1993-09-08 | 韦守源 | Making process for musk injection and injection thereof |
| CN1281716A (en) * | 1999-07-23 | 2001-01-31 | 王钢柱 | Medicine for curing diabetic peripheral neuropathy |
| US20050048144A1 (en) * | 2003-08-29 | 2005-03-03 | Xiao-Qing Han | Herb extract-based cosmeceutical cream for controlling the blood sugar level of diabetes and methods for making it |
| CN101648005A (en) * | 2008-08-13 | 2010-02-17 | 北京和润创新医药科技发展有限公司 | Medicinal composition for treating skin injury and ulcer and application thereof |
| CN102178758A (en) * | 2011-04-29 | 2011-09-14 | 薛红云 | Medicament for treating peripheral nerve of diabetes |
| KR20120072486A (en) * | 2010-12-24 | 2012-07-04 | 대전대학교 산학협력단 | Herbal medicnes for treating diabetic neuropathy |
| CN102727570A (en) * | 2012-07-11 | 2012-10-17 | 成都中医药大学附属医院 | External pharmaceutical composition for treating diabetic foot as well as preparation method and application of external pharmaceutical composition |
| CN102836274A (en) * | 2012-09-19 | 2012-12-26 | 董晓光 | Traditional Chinese medicine composition for treating dysfunction caused by injury of spinal cords and peripheral nerves |
| CN102895300A (en) * | 2012-05-23 | 2013-01-30 | 刘宗奎 | Traditional Chinese medicine compound capsule for reducing blood sugar, blood fat and blood pressure and preparation method thereof |
| CN106728871A (en) * | 2016-12-29 | 2017-05-31 | 安徽中医药大学 | A kind of Chinese medicine preparation for treating diabete peripheral herve pathology |
| CN107669788A (en) * | 2017-11-17 | 2018-02-09 | 陕西环珂生物科技有限公司 | A kind of traditional Chinese medicine lotion for treating diabete peripheral herve pathology and preparation method thereof |
| CN107789431A (en) * | 2017-11-17 | 2018-03-13 | 陕西环珂生物科技有限公司 | Treat Chinese medicine of diabete peripheral herve pathology and preparation method thereof |
| CN108057077A (en) * | 2018-02-09 | 2018-05-22 | 马飞 | Treat Chinese medicine composition of diabete peripheral herve pathology and preparation method thereof |
| CN108619473A (en) * | 2018-07-02 | 2018-10-09 | 汝州市济仁糖尿病医院 | A kind of Chinese medicine fuming-lotion for treating diabete peripheral herve pathology |
| KR20190129434A (en) * | 2018-05-11 | 2019-11-20 | 대전대학교 산학협력단 | a herb extraction composite for treating diabatic neuropathic insults |
| CN110623998A (en) * | 2019-09-11 | 2019-12-31 | 中国中医科学院中医临床基础医学研究所 | Traditional Chinese medicine composition for diabetic peripheral neuropathy and application thereof |
| CN111375009A (en) * | 2020-04-16 | 2020-07-07 | 上海市第七人民医院(上海中医药大学附属第七人民医院) | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy |
| CN112022929A (en) * | 2019-06-03 | 2020-12-04 | 鲁南制药集团股份有限公司 | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy and preparation method thereof |
| CN115054649A (en) * | 2022-06-30 | 2022-09-16 | 山东中医药大学第二附属医院(山东省中西医结合医院) | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy and preparation method thereof |
| CN115837058A (en) * | 2022-10-27 | 2023-03-24 | 江苏省中医院 | Traditional Chinese medicine composition, preparation thereof and application of traditional Chinese medicine composition in medicine for treating diabetic peripheral neuropathy |
-
2023
- 2023-07-21 CN CN202310905407.8A patent/CN116898941B/en active Active
Patent Citations (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1075880A (en) * | 1992-10-10 | 1993-09-08 | 韦守源 | Making process for musk injection and injection thereof |
| CN1281716A (en) * | 1999-07-23 | 2001-01-31 | 王钢柱 | Medicine for curing diabetic peripheral neuropathy |
| US20050048144A1 (en) * | 2003-08-29 | 2005-03-03 | Xiao-Qing Han | Herb extract-based cosmeceutical cream for controlling the blood sugar level of diabetes and methods for making it |
| CN101648005A (en) * | 2008-08-13 | 2010-02-17 | 北京和润创新医药科技发展有限公司 | Medicinal composition for treating skin injury and ulcer and application thereof |
| KR20120072486A (en) * | 2010-12-24 | 2012-07-04 | 대전대학교 산학협력단 | Herbal medicnes for treating diabetic neuropathy |
| CN102178758A (en) * | 2011-04-29 | 2011-09-14 | 薛红云 | Medicament for treating peripheral nerve of diabetes |
| CN102895300A (en) * | 2012-05-23 | 2013-01-30 | 刘宗奎 | Traditional Chinese medicine compound capsule for reducing blood sugar, blood fat and blood pressure and preparation method thereof |
| CN102727570A (en) * | 2012-07-11 | 2012-10-17 | 成都中医药大学附属医院 | External pharmaceutical composition for treating diabetic foot as well as preparation method and application of external pharmaceutical composition |
| CN102836274A (en) * | 2012-09-19 | 2012-12-26 | 董晓光 | Traditional Chinese medicine composition for treating dysfunction caused by injury of spinal cords and peripheral nerves |
| CN106728871A (en) * | 2016-12-29 | 2017-05-31 | 安徽中医药大学 | A kind of Chinese medicine preparation for treating diabete peripheral herve pathology |
| CN107669788A (en) * | 2017-11-17 | 2018-02-09 | 陕西环珂生物科技有限公司 | A kind of traditional Chinese medicine lotion for treating diabete peripheral herve pathology and preparation method thereof |
| CN107789431A (en) * | 2017-11-17 | 2018-03-13 | 陕西环珂生物科技有限公司 | Treat Chinese medicine of diabete peripheral herve pathology and preparation method thereof |
| CN108057077A (en) * | 2018-02-09 | 2018-05-22 | 马飞 | Treat Chinese medicine composition of diabete peripheral herve pathology and preparation method thereof |
| KR20190129434A (en) * | 2018-05-11 | 2019-11-20 | 대전대학교 산학협력단 | a herb extraction composite for treating diabatic neuropathic insults |
| CN108619473A (en) * | 2018-07-02 | 2018-10-09 | 汝州市济仁糖尿病医院 | A kind of Chinese medicine fuming-lotion for treating diabete peripheral herve pathology |
| CN112022929A (en) * | 2019-06-03 | 2020-12-04 | 鲁南制药集团股份有限公司 | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy and preparation method thereof |
| CN110623998A (en) * | 2019-09-11 | 2019-12-31 | 中国中医科学院中医临床基础医学研究所 | Traditional Chinese medicine composition for diabetic peripheral neuropathy and application thereof |
| CN111375009A (en) * | 2020-04-16 | 2020-07-07 | 上海市第七人民医院(上海中医药大学附属第七人民医院) | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy |
| CN115054649A (en) * | 2022-06-30 | 2022-09-16 | 山东中医药大学第二附属医院(山东省中西医结合医院) | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy and preparation method thereof |
| CN115837058A (en) * | 2022-10-27 | 2023-03-24 | 江苏省中医院 | Traditional Chinese medicine composition, preparation thereof and application of traditional Chinese medicine composition in medicine for treating diabetic peripheral neuropathy |
Non-Patent Citations (10)
| Title |
|---|
| 刘福平;陈彬;焦秀敏;: "复方川芎胶囊与银杏叶胶囊治疗糖尿病周围神经病变的疗效对比观察", 中西医结合心脑血管病杂志, no. 01, 10 January 2011 (2011-01-10), pages 8 - 10 * |
| 李琪;章宁静;高天;: "浴足方治疗糖尿病周围神经病变用药规律分析", 中药与临床, no. 02, 25 March 2018 (2018-03-25), pages 65 - 66 * |
| 李翠娟;巩振东;苗彦霞;: "中医药治疗糖尿病周围神经病变用药规律分析", 现代中医药, no. 04, 10 July 2010 (2010-07-10), pages 75 - 76 * |
| 杨达, 刘艾: "中西药治疗糖尿病性周围神经病变疗效观察", 新中医, no. 06, 15 June 1997 (1997-06-15), pages 32 * |
| 白兰萍;: "补阳还五汤治疗糖尿病周围神经病变的临床观察", 中医药信息, no. 06, 10 November 2006 (2006-11-10), pages 35 - 36 * |
| 董云飞;: "温经通络方外用治疗糖尿病多发性周围神经病变94例", 中国医药指南, no. 19, 10 July 2013 (2013-07-10), pages 690 - 691 * |
| 谢隆宾;: "补阳还五汤配合中药泡足治疗糖尿病周围神经病变疗效观察", 四川中医, no. 12, 15 December 2014 (2014-12-15), pages 110 - 112 * |
| 钱琪: "蛭归化瘀汤治疗糖尿病周围神经病变42例", 浙江中医杂志, no. 09, 25 September 2003 (2003-09-25), pages 382 * |
| 陈健, 刘铁球: "川芎茶调冲剂辅助治疗Ⅱ型糖尿病周围神经病变临床分析", 中药材, no. 07, 31 July 2001 (2001-07-31), pages 542 * |
| 韩丹丹;: "糖痛方治疗糖尿病周围神经病变疗效分析", 中国当代医药, no. 20, 18 July 2013 (2013-07-18), pages 128 - 129 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116898941B (en) | 2024-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007082425A1 (en) | A chinese medicine composition and its process and use | |
| CN111905084B (en) | Traditional Chinese medicine extract and preparation process and application thereof | |
| RU2485968C2 (en) | Drug preparation for treating diabetes and method for preparing it | |
| US10821149B2 (en) | Composition and the use thereof | |
| CN104352624B (en) | Application of the anaesthetic core fragrant plant n-butanol extract in preventing and treating diabetes medicament is prepared | |
| CN106362020B (en) | A kind of pine pollen composition and preparation method thereof with improvement defecating feces excretion | |
| WO2008061447A1 (en) | A medicine for treating eczema and process of ointment thereof | |
| CN104147394B (en) | A kind of dendrobium candidum compound preparation and preparation method thereof | |
| CN116898941B (en) | Traditional Chinese medicine composition and application thereof, traditional Chinese medicine preparation and preparation method and application thereof | |
| CN108853433A (en) | A kind of Chinese medicine and preparation method thereof for treating diabetic nephropathy | |
| CN110623998B (en) | Traditional Chinese medicine composition for diabetic peripheral neuropathy and application thereof | |
| CN1853679A (en) | Medicinal composition for treating cervical spondylosis and preparation thereof | |
| CN102228551A (en) | Chinese medicinal composition for preventing and treating injury of gastric mucosa and preparation method thereof | |
| CN104825753B (en) | A kind of Chinese medicine composition for prevention newborn piglet diarrhea of being taken medicine by sow | |
| CN103142933A (en) | Chinese herba preparation for treating disease of liver and gall in fish and preparation method thereof | |
| AU2018223375A1 (en) | Herbo-mineral formulation for prevention, treatment and management of diabetes and method of preparation thereof | |
| CN106975022A (en) | It is a kind of to treat Chinese medicine composition of cerebral apoplexy and its preparation method and application | |
| CN102085244B (en) | Chinese patent medicine for treating digestive system diseases | |
| CN102743456B (en) | The application of a kind of Chinese medicine composition in the medicine of preparation control delayed encephalopathy after acute carbon monoxide poisoning | |
| RU2094051C1 (en) | Medicinal preparation and a method of its preparing | |
| CN118045133A (en) | Application of trogopterus dung preparation in preparation of medicines for preventing or treating non-alcoholic fatty liver disease | |
| CN105796666A (en) | Diarrhoea-resistant traditional Chinese medicine composition and preparation | |
| CN105748844B (en) | A kind of oral Chinese medicine composition and preparation method thereof for treating migraine | |
| CN115645449A (en) | Method for processing cornus officinalis with double auxiliary materials, wine and honey and application of cornus officinalis | |
| CN103463222B (en) | A kind of Chinese medicine composition for the treatment of dysentery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |